Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
130.8 EUR | -0.68% | +2.03% | +40.94% |
07:46am | Novo Nordisk: FDA applications for icodec | CF |
06:32am | Novo Nordisk Receives Additional Information Request from US FDA for Insulin Icodec | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.22 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+40.94% | 628B | - | ||
+61.22% | 846B | C+ | ||
-4.66% | 360B | C+ | ||
+16.77% | 322B | B- | ||
+8.50% | 297B | C+ | ||
+13.94% | 240B | B+ | ||
+15.82% | 223B | B- | ||
+1.84% | 224B | A+ | ||
+11.68% | 173B | C+ | ||
-1.53% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVO B Stock
- NOV Stock
- Ratings Novo Nordisk A/S